Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 37: 1885-1890, 1991;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alderman, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alderman, M. H.

Clinical Chemistry, Vol 37, 1885-1890, Copyright © 1991 by American Association for Clinical Chemistry

Heterogeneity among hypertensive subjects: a tool for clinical decision- making

MH Alderman
Department of Epidemiology and Social Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY 10461.

Current antihypertensive treatment strategy tends to approach all patients similarly, with decision to treat, the goal of treatment, and medication use based largely on blood pressure measurement. Clearly, it would make far more sense if a management strategy could be developed that was not solely dependent on measurement of blood pressure, but rather reflected a clearer understanding of individual likelihood of adverse outcome, the nature of blood pressure control, and the importance of associated clinical and biological characteristics. New tools make it possible to accurately assess the status of the heart, kidney, and blood vessels, both as a guide to the need for therapy and as a measure of treatment progress when the treatment is used. New understanding of the vasoconstrictor and volume contributions to blood pressure control coupled with a rich armamentarium of therapeutic agents make it possible to tailor therapy more appropriately. Finally, growing awareness of the contribution of concomitant risk factors has made it clear that overall success depends on attention to the whole patient.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American Association for Clinical Chemistry.